These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30442177)

  • 1. Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches.
    Fraldi A; Serafini M; Sorrentino NC; Gentner B; Aiuti A; Bernardo ME
    Ital J Pediatr; 2018 Nov; 44(Suppl 2):130. PubMed ID: 30442177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex Vivo and In Vivo Gene Therapy for Mucopolysaccharidoses: State of the Art.
    Consiglieri G; Bernardo ME; Brunetti-Pierri N; Aiuti A
    Hematol Oncol Clin North Am; 2022 Aug; 36(4):865-878. PubMed ID: 35773049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnology applied to treatment of mucopolysaccharidoses.
    Schuh RS; Baldo G; Teixeira HF
    Expert Opin Drug Deliv; 2016 Dec; 13(12):1709-1718. PubMed ID: 27322551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.
    Lau AA; Hemsley KM
    J Mol Med (Berl); 2017 Oct; 95(10):1043-1052. PubMed ID: 28660346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of brain disease in the mucopolysaccharidoses.
    Scarpa M; Orchard PJ; Schulz A; Dickson PI; Haskins ME; Escolar ML; Giugliani R
    Mol Genet Metab; 2017 Dec; 122S():25-34. PubMed ID: 29153844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art.
    de Castro MJ; Del Toro M; Giugliani R; Couce ML
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for Mucopolysaccharidoses.
    Sawamoto K; Chen HH; Alméciga-Díaz CJ; Mason RW; Tomatsu S
    Mol Genet Metab; 2018 Feb; 123(2):59-68. PubMed ID: 29295764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and new therapies for mucopolysaccharidoses.
    Penon-Portmann M; Blair DR; Harmatz P
    Pediatr Neonatol; 2023 Feb; 64 Suppl 1():S10-S17. PubMed ID: 36464587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Principles of therapeutic approaches for mucopolysaccharidoses].
    Caillaud C
    Arch Pediatr; 2014 Jun; 21 Suppl 1():S39-45. PubMed ID: 25063383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy for neurologic manifestations of mucopolysaccharidoses.
    Wolf DA; Banerjee S; Hackett PB; Whitley CB; McIvor RS; Low WC
    Expert Opin Drug Deliv; 2015 Feb; 12(2):283-96. PubMed ID: 25510418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments.
    Sawamoto K; Stapleton M; Alméciga-Díaz CJ; Espejo-Mojica AJ; Losada JC; Suarez DA; Tomatsu S
    Drugs; 2019 Jul; 79(10):1103-1134. PubMed ID: 31209777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene delivery strategies for the treatment of mucopolysaccharidoses.
    Baldo G; Giugliani R; Matte U
    Expert Opin Drug Deliv; 2014 Mar; 11(3):449-59. PubMed ID: 24450877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.
    Pan D
    Curr Pharm Biotechnol; 2011 Jun; 12(6):884-96. PubMed ID: 21235445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for the treatment of mucopolysaccharidoses.
    Giugliani R; Federhen A; Vairo F; Vanzella C; Pasqualim G; da Silva LM; Giugliani L; de Boer AP; de Souza CF; Matte U; Baldo G
    Expert Opin Emerg Drugs; 2016; 21(1):9-26. PubMed ID: 26751109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.
    Peck SH; Casal ML; Malhotra NR; Ficicioglu C; Smith LJ
    Mol Genet Metab; 2016 Aug; 118(4):232-43. PubMed ID: 27296532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapies for mucopolysaccharidoses.
    Rossi A; Brunetti-Pierri N
    J Inherit Metab Dis; 2024 Jan; 47(1):135-144. PubMed ID: 37204267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
    Banecka-Majkutewicz Z; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Węgrzyn A; Węgrzyn G
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):461-8. PubMed ID: 22949095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and potential therapeutic strategies for mucopolysaccharidoses.
    Noh H; Lee JI
    J Clin Pharm Ther; 2014 Jun; 39(3):215-24. PubMed ID: 24612142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and Emerging Therapies for Mucopolysaccharidoses.
    Lagler FB
    Handb Exp Pharmacol; 2020; 261():39-56. PubMed ID: 31451968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets.
    Leal AF; Benincore-Flórez E; Rintz E; Herreño-Pachón AM; Celik B; Ago Y; Alméciga-Díaz CJ; Tomatsu S
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.